<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01834222</url>
  </required_header>
  <id_info>
    <org_study_id>B1851143</org_study_id>
    <nct_id>NCT01834222</nct_id>
  </id_info>
  <brief_title>Post Market Surveillance to Observe Safety of Prevenar13™ in Adults</brief_title>
  <official_title>Post Marketing Surveillance to Observe Safety of Prevenar 13 in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety profile of Prevenar 13™ when used among Korean
      adults in the routine clinical setting, as required for any new drug approved by Korea Food
      and Drug Administration (KFDA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      non-randomization, non-probability sampling
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety profile following administration of Prevenar13- Clinical nature, frequency, duration, severity of adverse events; discontinuation due to adverse events; outcome and possible causality</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pneumococcal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-intervention</intervention_name>
    <description>Non-intervention</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Non-intervention</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical
        setting
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Korean adults aged 50 years and older; provided the conditions pertaining to
             contraindications, warnings, precautions, and interactions stated in the local
             product document do not apply.

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject(or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.

        Exclusion Criteria:

          -  Subjects who are not indicated and/or contraindicated for the Prevenar13 usage will
             not be included.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Lee's Medical Clinic</name>
      <address>
        <city>GwangJu</city>
        <zip>501-190</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bundang 21st Clinic</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>463-823</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1851143&amp;StudyName=Post%20Market%20Surveillance%20to%20Observe%20Safety%20of%20Prevenar13%u2122%20in%20Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>April 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
